PRIME unites a multidisciplinary team of 17 European Institutions, which are internationally leading players in their disciplines (from internal medicine to psychiatry), with SMEs in fast-developing areas of translation of science into societal impact and relevant societal partners. With this team, we are in a perfect position to reach the ambitious goal to innovate the understanding of insulin co-occurring diseases and improve the diagnosis, prognosis, therapy development, management and prevention of co- and multimorbidity among the insulin-related conditions. Our work will open up entirely new directions for clinical research through the identification of new ‘insulinopathies’ and the characterization of their lifespan developmental nature, time course, interdependence and gender differences.